Perspectives on cutting-edge nanoparticulate drug delivery technologies based on lipids and their applications

被引:16
|
作者
Maddiboyina, Balaji [1 ,4 ]
Nakkala, Ramya Krishna [1 ,2 ]
Roy, Harekrishna [3 ]
机构
[1] Phoenix SEZ, Freyr Solut, Hyderabad, Telangana, India
[2] Vishwa Bharathi Coll Pharmaceut Sci, Guntur, Andhra Pradesh, India
[3] Nirmala Coll Pharm, Guntur, Andhra Pradesh, India
[4] Freyr Solut, Dept Med Writing, Med Prod, Hyderabad 500081, Telangana, India
关键词
lipid nanoparticles; liposomes; micelles; Niosomes; solid-lipid nanoparticles; IN-VITRO; ORAL BIOAVAILABILITY; LIPOSOMAL DOXORUBICIN; MULTIDRUG-RESISTANCE; TISSUE DISTRIBUTION; FORMULATION DESIGN; POLYMERIC MICELLES; CIRCULATION TIME; SKIN PERMEATION; BREAST-CANCER;
D O I
10.1111/cbdd.14230
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Numerous nanotech arenas in therapeutic biology have recently provided a scientific platform to manufacture a considerable swath of unique chemical entities focusing on drugs. Recently, nanoparticulate drug delivery systems have emerged to deliver a specific drug to a specified site. Among all other carriers, lipids possess features exclusive to nanostructured dosage forms. The bioavailability of orally administered drugs is typically negatively affected by their poor water solubility, resulting from the unique chemical moieties introduced. Because of their unique advantages, lipid nanoparticles must become increasingly predictable as a robust delivery mechanism. The enhanced biopharmaceutical properties and significance of lipid-based targeting technologies such as liposomes, niosomes, solid lipid nanoparticles and micelles are highlighted in this review. Pharmaceutical implications of lipid nanocarriers for the transport and distribution of various therapeutic agents, such as biotechnological products and small pharmaceutical molecules, is a booming topic. Lipid nanoparticles as drug delivery systems have many appealing properties, including high biocompatibility, ease of preparation, tissue specificity, avoidance of reticuloendothelial systems, delayed drug release, scale-up feasibility, nontoxicity and targeted delivery. The use of lipid nanoparticles to enhance the transport of biopharmaceuticals is currently considered state-of-the-art. Similarly, we critically examine the upcoming guidelines that therapeutic scientists should handle.
引用
收藏
页码:377 / 394
页数:18
相关论文
共 50 条